Concussion Technology and Insurance: Wearables, AI Diagnostics, and Athletic Brain Protection in 2026

When the NHL began deploying smart helmet technology and concussion spotters with access to video review during the 2022-23 season — personnel watching live and recorded footage specifically to identify players who may have sustained concussions — it represented a technological and procedural evolution in how professional sports manages brain injury risk. This is just one dimension of a broader technological revolution reshaping concussion management: impact sensors embedded in helmets and mouthguards, blood biomarker tests for concussion diagnosis, eye-tracking-based sideline assessment tools, AI-powered video analysis, and neurocognitive monitoring apps. These technologies are transforming how concussions are detected, managed, and documented. Concussion technology and insurance interact in increasingly important ways — the data these technologies generate has direct implications for how insurance claims are documented, how insurers assess risk, and potentially how prevention is incentivized through insurance pricing.

This guide explores the intersection of emerging concussion technology and athletic insurance: how the data generated by these tools affects insurance claims, what insurers are doing with concussion technology data, how athletes can use technology for both health protection and insurance documentation, and what the near-future of technologically-informed athlete brain insurance looks like.

Impact Monitoring Technology

Helmet Sensors

Accelerometer-based helmet sensors — embedded in or attached to the helmet — measure linear and rotational acceleration during head impacts. Systems like HITS (Head Impact Telemetry System) and current commercial helmet sensor products provide real-time data on impact magnitude, frequency, and cumulative exposure. When an impact exceeds a defined threshold, sideline medical staff are alerted for immediate evaluation. From an insurance perspective, this data provides:

• Objective injury documentation: Sensor data timestamped to the moment of impact creates a data record that corroborates an athlete's concussion claim — replacing or supplementing the historical reliance on subjective symptom reporting
• Exposure data for underwriting: Cumulative impact data over a career could theoretically inform disability and long-term care insurance underwriting for athletes with high lifetime impact exposure
• Research contribution: Population-level sensor data advances understanding of the biomechanical thresholds that predict concussion risk

Smart Mouthguard Technology

Smart mouthguards with embedded acceleration sensors — products like PREVENT Biometrics and FITGuard — measure head impacts during practice and competition from the athlete's own head motion rather than from the helmet. Mouthguard sensors are increasingly adopted at elite levels of rugby, hockey, and football, providing a more accurate biomechanical measure of head acceleration than helmet-mounted sensors. The data is transmitted in real-time to sideline devices and stored for post-session analysis. Like helmet sensors, smart mouthguard data creates objective documentation of impact events that can support or contextualize concussion claims.

Wearable Cervical Sensors

Cervical (neck) mounted sensors measure head impacts transmitted through the cervical spine — an alternative location for impact measurement that correlates with brain acceleration during head impacts. These systems are particularly relevant for sports without standard helmets — rugby, soccer, women's lacrosse — where helmet-integrated sensing is not practical. Providing impact monitoring for athletes in non-helmeted sports broadens the data collection available for both clinical management and insurance documentation.

Diagnostic Technology for Concussion Assessment

Blood Biomarker Tests

In 2018, the FDA approved the first blood test for concussion diagnosis — the Abbott i-STAT TBI test measuring GFAP and UCH-L1 biomarkers released by damaged brain cells into the bloodstream. A positive blood biomarker test provides objective confirmation of brain injury at a molecular level — significantly stronger evidence than symptom reporting alone. The test is now used in emergency settings and sports medicine, with NFL sideline implementation beginning in recent seasons. For insurance claims management, a positive biomarker test creates unambiguous objective documentation of traumatic brain injury that eliminates the "he said/she said" uncertainty that has historically complicated some concussion claims disputes.

Eye-Tracking Concussion Diagnostics

Concussions affect the ocular-motor system — the neurological pathways controlling eye tracking and visual coordination. Devices like King-Devick test and RightEye's EyeQ technology assess eye movement abnormalities that indicate concussion-related neurological disruption. These tests can be administered in minutes on the sideline, providing rapid objective concussion screening beyond symptom checklists and balance assessments. For insurance documentation, eye-tracking test results provide another layer of objective data supporting or contesting concussion claims.

AI-Powered Video Concussion Detection

Artificial intelligence applied to sports video — the same video used for performance analysis — is increasingly capable of detecting concussion indicators in athlete movement and behavior after head impacts: unusual stumbling, ataxic gait, protective reach when falling, and other behavioral markers that indicate neurological disruption. The NHL's video spotter program uses both human observation and computer assistance; similar systems are being developed for football and rugby. AI video detection creates a passive, continuous concussion surveillance system that does not depend on athletes self-reporting symptoms — which historically occurs at dramatically lower rates than actual concussion incidence.

Technology's Interaction with Insurance

Claims Documentation Enhancement

The most immediate insurance value of concussion technology is enhanced claims documentation. Athletes with objective sensor data, biomarker test results, and eye-tracking assessments documenting the specific impact event and acute neurological disruption have substantially stronger insurance claims than those relying solely on symptom reporting and physician examination. In disability insurance claims where the causation of neurological symptoms is disputed — "was this from sports or from something else?" — objective impact data from sensor records provides critical evidence.

Underwriting Data Implications

As impact sensor data accumulates at population scale — particularly through mandatory sensor programs in professional leagues and voluntary programs at lower levels — insurers will eventually have data to support more actuarially precise underwriting of athletes based on their documented cumulative impact exposure rather than simple sport classification. An athlete with 10 years of low-exposure sensor data might present differently to a disability underwriter than one with equivalent career length but very high cumulative impact data. This data-informed underwriting is not yet mainstream, but it represents a credible near-future development in athletic insurance.

Prevention Incentives Through Insurance

Some insurance innovators are exploring whether concussion monitoring technology adoption can be incentivized through insurance pricing — similar to how telematics programs reward safe drivers with auto insurance discounts. An athlete who demonstrates consistent use of impact monitoring technology, demonstrates compliance with concussion protocols, and produces data showing appropriate impact management might qualify for reduced disability insurance premiums reflecting genuinely lower risk. This model does not yet exist at scale but represents a logical extension of the telematics insurance concept to athletic brain injury risk management.

Athletes' Rights in the Data Economy

Ownership and Control of Biometric Data

As concussion sensor data, biomarker test results, and AI video analysis accumulate for individual athletes, questions about who owns that data and how it can be used become important. Data collected by teams or leagues may be accessed by insurers — with athlete consent or through HIPAA-compliant data sharing arrangements — potentially affecting both claims management and future underwriting. Athletes should understand who owns the data generated by team-administered monitoring programs and what restrictions exist on its use beyond the immediate clinical purpose.

GDPR and International Data Protection

For athletes competing internationally, European GDPR and other national data protection frameworks impose restrictions on health biometric data use by employers, insurers, and other entities. Athletes competing in European leagues — Premier League, Champions League, Top 14 rugby — have GDPR protections that limit how their sensor and biomarker data can be shared with insurers without explicit, informed consent. Understanding these protections is increasingly important as biometric data collection in sport expands.

Frequently Asked Questions

Can I be required by my insurer to use concussion monitoring technology?

Currently, no insurer mandates concussion monitoring technology use as a condition of coverage for individual athletes. Employers (teams) can implement monitoring programs as part of their workplace safety and medical management protocols — separate from individual athletes' personal insurance. Future insurance products might offer voluntary technology adoption with premium incentives, similar to current auto telematics programs. Mandatory requirements for insurance eligibility would raise significant legal and ethical concerns around biometric surveillance that make them unlikely in the near term.

How does AI video concussion detection affect a player's right to continue playing?

When AI video detection flags a player as potentially concussed, that flag initiates a clinical evaluation process — the technology identifies candidates for examination, not final return-to-play determinations. The clinical decision remains with the team physician or designated medical officer. However, the AI flag creates a documented record that an evaluation should have been conducted — if a player is not evaluated after an AI flag and subsequently sustains further injury, the failure to act on the flag becomes relevant in liability analysis. Technology shifts the burden of justifying return-to-play without evaluation from the player (who might not report symptoms) to the organization (which must document why the clinical evaluation concluded no concussion was present).

Are blood biomarker concussion tests covered by health insurance?

The Abbott i-STAT TBI test is covered by health insurance when ordered by a physician in an emergency department setting for evaluation of a suspected head injury. As the test becomes more widely used in sports medicine office settings, coverage for non-emergency use is evolving. Some insurers have added coverage for outpatient blood biomarker testing for sports concussion evaluation when ordered by a sports medicine physician with clinical documentation of the evaluation rationale. Check with your specific health plan for current coverage of this specific diagnostic test.

How do I use sensor data to support a disability insurance claim?

Compile all available objective data about your impact history and concussion events: sensor data records from helmet or mouthguard systems, documentation of any blood biomarker tests, neuropsychological test results, physician evaluations noting clinical concussion diagnoses, and return-to-play protocol records. Present this comprehensive documentation to your disability insurer and treating physicians as part of the medical evidence package supporting your claim. The more objective, technology-generated documentation you can provide, the stronger your claim documentation relative to one based solely on subjective symptom reporting.

Will impact monitoring technology make brain injury insurance more or less expensive for athletes?

The long-term effect on insurance pricing could go either direction. If technology data enables more precise risk identification — identifying athletes with genuinely lower impact exposure who are better risks — those athletes may benefit from lower premiums. If technology reveals that previously underestimated concussion rates and cumulative exposure in certain sports represent higher actuarial risk than previously priced, premiums for those sports may increase. In the near term, technology adoption is more likely to improve claims documentation quality and protocol compliance monitoring than to directly affect premium pricing.

Conclusion

The NHL's concussion spotters and smart helmet programs, the blood biomarker tests in NFL sideline medical kits, and the eye-tracking devices used in rugby's Head Injury Assessment protocol represent the leading edge of a technological revolution in athletic brain injury management. For athletes, these technologies provide better, faster concussion identification that enables proper management. For insurers, the objective data these technologies generate strengthens claims documentation and potentially enables more sophisticated risk pricing. For the broader sports insurance ecosystem, the intersection of wearable technology, AI diagnostics, biometric data, and insurance represents a frontier that will reshape athletic brain protection planning over the next decade. Athletes who adopt monitoring technology, maintain comprehensive objective records of their brain health, and engage proactively with insurance documentation best practices are building the strongest possible foundation for brain injury insurance claims and financial protection in the technologically transformed sports medicine landscape of 2026 and beyond.